Red Hoffman, a partner in Greylock and co -founder LinkedIn, speaks during the WSJ Tech Live Conference hosted by The Wall Street Journal at Montage Laguna Beach at Laguna Beach, California, on October 21, 2024.
Friedrich J. Brown AFP | Gety pictures
Founder participating in LinkedIn and project capitalism Red Hoffman The billionaire has become a commercial social work company, and it has made profitable bets on companies, including Airbnb And Zynga also while supporting the startup also Heilon Energy.
Hoffman is now dining in health care, which he describes as “amazing and terrifying”, with the last starting start, Manas AI.
Hoffmann and Dr. Sidhathta Mukirji, a Politzer Prize -winning author, Politzer, unveil The company on Monday. Manas will use artificial intelligence to try to accelerate the process of drug detection, from new treatments for aggressive cancer such as prostate cancer, lymph nodes and negative triple breast cancer.
The development of new drugs is traditionally expensive and complex. It may take more than 10 years and cost billions of dollars to develop one drug, according to a report from Deluette. Manas said it would use its own chemical libraries and powered by artificial intelligence to identify drug candidates more quickly, which perfectly reduces the decades -to -a -decades discovery process.
“Most people had friends and family members, etc., who died due to cancer or suffering from serious cancer problems,” Hoffman told CNBC in an interview this week. “If we are able to make a major change in this matter, and this is the thing in which Amnesty International can make a big difference, this is a kind of reason that artificial intelligence can be great for humanity.”
Manas raised $ 24.6 million in seed financing, led General catalyst Hoffman with the participation of Greylock, where he is a partner. Hoffman has been deep in artificial intelligence in recent years. He was an early investor in Openai, when the project was still a non -profit organization, and helped start a turbulence of artificial intelligence with the founder of DeepMind Mustafa Soleyman. Last year, Solomon joined MicrosoftWhere Hoffman is a member of the Board of Directors, as CEO of a new unit called Microsoft Ai. Join many reflection employees.
Manas has also supplied a partnership with MicrosoftAnd it will benefit from the azure cloud computing platform. Hoffman, who sold LinkedIn to Microsoft for $ 27 billion, said that Manas publishes many additional tools from Microsoft as well, including some of them are generally not available to the public so far.
Hoffman works with Mukherje to create Manas for about a year, although the process has taken Steam in the past two months. Hoffman said that the team felt that he was ready to publicly share its aspirations this week since the basic line, the establishment resources in good condition.
“Fullly pleased” to see the competition
The company has a long road forward, and the drug detection market is very competitive. Other startups along with major pharmaceutical companies such as Eli Lilyand Vizar and MerkThey also explore how to take advantage of artificial intelligence to accelerate drug research and development.
Hoffman said he was confident in Manas's approach, although he will be “completely pleased” to see many companies flourish.
“We also come something that usually brings the startup, and it is ready to go very much, and to give up things quickly does not work,” he said. “Living such a week is important, and as a result of this week is important.”
After the launch of Manas on Monday, five different potential strategic partners approached the company, Hoffmann said.
Hoffman said that the company is in “Build” and “Learn and Publishing”. It is called one of its early initiatives, which is an attempt to clarify the basic rules for the connection of the drug, according to the company's website. Hoffman refused to share any additional details about the project.
Manas currently has only four employees – including Hoffman and Moghiri – but Hoffman said it will grow. He said he behaves as the company's “artificial intelligence man” while Mukherji works as “Bio Guy”. Ultimately, Manas revolves around mixing fields.
“This is not just better in science and not only better than artificial intelligence, because any of these two is not enough,” Hoffman said. “You need to put these two together.”
As an artificial intelligence man, Hoffmann was closely attention this week to the sudden appearance of Deepseek in China in the United States
Deepseek started in the generation of Buzz in January, when Startup released the R1 R1, which competes with Openai's O1. According to what was reported, the model was developed on a small part of the cost of competing models by Openai, anthropology, Google And others.
Hoffman said that although Deepseek may encourage American companies to capture the pace and share their plans sooner, the new revelation does not indicate that large models are a bad investment.
He said: “The competition game is running, but I don't think it is” my God, we lose! As an American technology.
He watches: Participant founder of LinkedIn Red Hoffman
